Efavirenz has a long and variable half-life of 40-55 hours at steady state.2 Therapeutic concentrations have been measured up to several weeks after drug intake cessation in some patients.3 Efavirenz is an inducer of hepatic cytochrome P450 (CYP450), a group of enzymes involved in the metabolism of a wide variety of drugs.4 Induction of CYP3A4 leads to reductions in plasma concentrations of coadministered drugs that are metabolized by CYP3A4, potentially diminishing their therapeutic effects.5-7 Moreover, efavirenz itself is primarily metabolized by CYP2B6 and racially distributed pharmacogenetic differences in CYP2B6 activity seem to contribute to the high interindividual variability in efavirenz exposure.8 Etravirine, a next generation NNRTI, is approved for use in combination with other ARVs in treatment-experienced patients.9 Unlike older NNRTIs, etravirine retained efficacy in the presence of some common NNRTI-associated resistance mutations
L., Young, T
GLP-1 microdosing may represent part of this evolution, offering a more nuanced approach to metabolic health optimization
Talk with a licensed healthcare professional before beginning any prescription weight-management protocol, particularly if you have an existing medical condition, take other medications or supplements, are pregnant or nursing, or have a history of pancreatitis, gallbladder disease, an endocrine disorder, an eating disorder, or another relevant health concern
What the Clinical Evidence Shows The fact that CJC-1295/Ipamorelin lacks FDA approval does not mean it lacks clinical evidence
